Inhibition of Leptin and Leptin Receptor Gene Expression by Silibinin-Curcumin Combination

  • Nejati-Koshki, Kazem (Department of Medical Biotechnology, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Akbarzadeh, Abolfazl (Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences) ;
  • Pourhasan-Moghaddam, Mohammad (Department of Medical Biotechnology, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Abhari, Alireza (Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Dariushnejad, Hassan (Department of Medical Biotechnology, Faculty of Medicine, Tabriz University of Medical Sciences)
  • Published : 2013.11.30


Leptin and its receptor are involved in breast carcinogenesis as mitogenic factors. Therefore, they could be considered as targets for breast cancer therapy. Expression of the leptin receptor gene could be modulated by leptin secretion. Silibinin and curcumin are herbal compounds with anti-cancer activity against breast cancer. The aim of this study was to assess their potential to inhibit of expression of the leptin gene and its receptor and leptin secretion. Cytotoxic effects of the two agents on combination on T47D breast cancer cells was investigated by MTT assay test after 24h treatment. With different concentrations the levels of leptin, leptin receptor genes expression were measured by reverse-transcription real-time PCR. Amount of secreted leptin in the culture medium was determined by ELISA. Data were statistically analyzed by one-way ANOVA test. The silibinin and curcumin combination inhibited growth of T47D cells in a dose dependent manner. There were also significant difference between control and treated cells in leptin expression and the quantity of secreted leptin with a relative decrease in leptin receptor expression. In conclusion, these herbal compounds inhibit the expression and secretion of leptin and it could probably be used as drug candidates for breast cancer therapy through leptin targeting in the future.



  1. Boominathan, Lakshmanane (2009). Curcumin Functions as a Positive Regulator of miRNA Processing & a Negative Regulator of Cancer Stem Cell Proliferation.
  2. Chiu TL, Su CC (2009). Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med, 23, 469-75.
  3. Cottrell EC, Mercer JG (2012). Leptin receptors. Handb Exp Pharmacol, 3-21.
  4. De Kok TM, van Breda SG, Manson MM (2008). Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr, 47, 51-9.
  5. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, et al (2002). Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 293, 622-8.
  6. Fazeli M, Zarkesh-Esfahani H, Wu Z, et al (2006). Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. J Immunol Methods, 312, 190-200.
  7. Fusco R, Galgani M, Procaccini C, et al (2010). Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer, 17, 373-82.
  8. Garcia-Robles MJ, Segura-Ortega JE, Fafutis-Morris M (2013). The biology of leptin and its implications in breast cancer: a general view. J Interferon Cytokine Res, [Epub ahead of print].
  9. Go O, Freeman RH, Reams GP, et al (2013). Obesity hypertension: pathophysiological role of leptin in neuroendocrine dysregulation. Am J Med Sci, [Epub ahead of print]
  10. Gonzalez RR, Watters A, Xu Y, et al (2009). Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res, 11, 36.
  11. Hardwick JC, Van Den Brink GR, Offerhaus GJ, et al (2001). Leptin is a growth factor for colonic epithelial cells. Gastroenterology, 121, 79-90.
  12. Hu X, Juneja SC, Maihle NJ, et al (2002). Leptin.a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst, 94, 1704-11.
  13. Ishikawa M, Kitayama J, Nagawa H (2004). Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res, 10, 4325-31.
  14. Kaur M, Agarwal R (2007). Silymarin and epithelial cancer chemoprevention: how close we are to bedside. Toxicol Appl Pharmacol, 224, 350-9.
  15. Kelesidis T, Kelesidis I, Chou S, et al (2010). Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med, 152, 93-100.
  16. Koda M, Sulkowska M, Kanczuga-Koda L, et al (2007). Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folia Histochem Cytobiol, 45, 187-91.
  17. Laud K, Gourdou I, Pessemesse L, et al (2002). Identification of leptin receptors in human breast cancer: Functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol, 188, 219-26.
  18. Lin CJ, Sukarieh R, Pelletier J (2009). Silibinin inhibits translation initiation: implications for anticancer therapy. Mol Cancer Ther, 8, 1606-12.
  19. Liu Z, Uesaka T, Watanabe H, et al (2001). High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol, 19, 1009-14.
  20. Loffler S, Aust G, Kohler U, et al (2001). Evidence of leptin expression in normal and polycystic human ovaries. Mol Hum Reprod, 7, 1143-9.
  21. Maymo JL, Perez AP, Gambino Y, et al (2011). Leptin gene expression in the placenta--regulation of a key hormone in trophoblast proliferation and survival. Placenta, 2, 146-53.
  22. Mix H, Widjaja A, Jandl O (2000). Expression of leptin and leptin receptor isoforms in the human stomach. Gut, 47, 481-6.
  23. Morroni M, De Matteis R, Palumbo C, et al (2004). In vivo leptin expression in cartilage and bone cells of growing rats and adult humans. J Anat, 205, 291-6.
  24. Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, et al (2012). Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology, 64, 719-26.
  25. Oda A, Taniguchi T, Yokoyama M (2001). Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci, 47, 141-50.
  26. Peters JH, Simasko SM, Ritter RC (2007). Leptin analog antagonizes leptin effects on food intake and body weight but mimics leptin-induced vagal afferent activation. Endocrinology, 148, 2878-85.
  27. Ray A, Cleary MP (2010). Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets, 14, 443-51.
  28. Sareen R, Jain N, Pandit V (2013). Curcumin: A boon to Colonic Diseases. Curr Drug Targets, 14. [Epub ahead of print]
  29. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics 2012. CA Cancer J Clin, 62, 10-29.
  30. Singh RP, Sharma G, Dhanalakshmi S, et al (2009). Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Mol Cancer Ther, 8, 1606-12.
  31. Solberg R, Aas V, Thoresen GH, et al (2005). Leptin expression in human primary skeletal muscle cells is reduced during differentiation. J Cell Biochem, 96, 89-96.
  32. Soyupek S, A, Serel TA, et al (2005). Leptin expression in the testicular tissue of fertile and infertile men. Arch Androl, 51, 239-46.
  33. Wazir U, Al Sarakbi W, Jiang WG, et al (2012). Evidence of an autocrine role for leptin and leptin receptor in human breast cancer. Cancer Genomics Proteomics, 9, 383-7.
  34. Yi KW, Shin JH, Seo HS, et al (2008). Role of estrogen receptor-alpha and -beta in regulating leptin expression in 3T3-L1 adipocytes. Obesity (Silver Spring), 16, 2393-9.
  35. Yom CK, Lee KM, Han W, et al (2013). Leptin as a potential target for estrogen receptor-positive breast cancer. J Breast Cancer, 16, 138-45.

Cited by

  1. Magnetic Nanocomposites Based on Poly(N-isopropylacrylamide) for Anti-cancer Drug Delivery vol.15, pp.1, 2014,
  2. Molecular Target Therapy of AKT and NF-kB Signaling Pathways and Multidrug Resistance by Specific Cell Penetrating Inhibitor Peptides in HL-60 Cells vol.15, pp.10, 2014,
  3. Trichostatin A-induced Apoptosis is Mediated by Krüppel-like Factor 4 in Ovarian and Lung Cancer vol.15, pp.16, 2014,
  4. Silibinin Inhibits Proliferation, Induces Apoptosis and Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells Via STAT3 Pathway Inhibition vol.15, pp.16, 2014,
  5. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014,
  6. Silver nanoparticles: Synthesis methods, bio-applications and properties pp.1549-7828, 2014,
  7. Magnetic nanoparticles: Applications in gene delivery and gene therapy pp.2169-141X, 2015,
  8. Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines pp.2169-141X, 2015,
  9. Upregulation of Mir-34a in AGS Gastric Cancer Cells by a PLGA-PEG-PLGA Chrysin Nano Formulation vol.16, pp.18, 2016,
  10. Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis vol.31, pp.12, 2017,
  11. Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases vol.36, pp.4, 2017,
  12. Preparation and characterization of PLGA-β-CD polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line vol.45, pp.3, 2017,
  13. Molecular targets for the therapy of cancer associated with metabolic syndrome (transcription and growth factors) pp.17437555, 2017,